Compare Entegris Inc (ENTG) vs Novavax Inc (NVAX) Price & Performance

ENTG trades at $162.19, down 2.48% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 29, 2026. Revenue for 2025 was $3.20B, with a net income margin of 7.37%. Analyst consensus is strongly bullish, with a price target of $182.43, indicating a 12.5% upside. Recent news highlights strong AI-driven semiconductor demand and institutional buying interest.

The outlook for ENTG is positive, supported by robust earnings performance and growing demand in the semiconductor sector. Key opportunities include expansion in AI-related markets and operational efficiency gains. Risks involve high valuation multiples, competitive pressures, and sensitivity to semiconductor industry cycles. Investors should weigh the strong analyst support against potential market volatility and execution challenges.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.